EP1173148A1 - Methode pour ameliorer l'aspect esthetique de l'epithelium - Google Patents

Methode pour ameliorer l'aspect esthetique de l'epithelium

Info

Publication number
EP1173148A1
EP1173148A1 EP00928558A EP00928558A EP1173148A1 EP 1173148 A1 EP1173148 A1 EP 1173148A1 EP 00928558 A EP00928558 A EP 00928558A EP 00928558 A EP00928558 A EP 00928558A EP 1173148 A1 EP1173148 A1 EP 1173148A1
Authority
EP
European Patent Office
Prior art keywords
epithelia
lip
composition
retinoid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00928558A
Other languages
German (de)
English (en)
Other versions
EP1173148A4 (fr
Inventor
Dennis M. Martin
Michael Traudt
Paul Attar
Isabella Morelli-Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avon Products Inc
Original Assignee
Avon Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avon Products Inc filed Critical Avon Products Inc
Publication of EP1173148A1 publication Critical patent/EP1173148A1/fr
Publication of EP1173148A4 publication Critical patent/EP1173148A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal

Definitions

  • the present invention relates to a method of improving or re- moisturizing the epithelia. More particularly, the present invention relates to a method of improving lip color and reducing the number and depth of lip lines on the surface of the lips, as well as re-moisturizing the vagina and lips. This is achieved by using a composition comprising a retinoid, such as retinol, and a penetration enhancing agent in a cosmetically acceptable carrier.
  • the present invention also relates to a composition, which comprises a retinoid, and to a process for preparing the composition.
  • Retinol is known for its beneficial effects in the treatment of acne. In the field of repair of damage caused either by age or overexposure to the sun, retinol has been proven beneficial. Repeated application of cosmetic compositions containing retinol has been used to smooth the skin surface, repair small cracks in the epidermis and to remove wrinkles or minimize the formation thereof.
  • retinol for re-moisturizing, treating a color deficiency and/or treating vertical lines, does not have an obvious correlation to skin aging pathologies.
  • vertical lip lines are visually distinguishable from general wrinkling of the lips.
  • vertical lip lines appear as substantially vertical creases, whereas "wrinkling” has no such discernible form.
  • orally administered retinoids such as, for example, retinol and retinoic acid, dry out the epithelia and cause cornification of mucosal epithelia.
  • retinoid such as retinol
  • a penetration enhancing agent to mucosal or semi-mucosal epithelium that is dried out and/or cornified, re-moisturizes the epithelium. Furthermore, with repeated application, the cornified epithelia returns to its original mucosal state.
  • U.S. Patent No. 4,826,828 is directed to a water-in-oil emulsion containing retinol, a volatile silicone and a solvent for both the retinol and the volatile silicones.
  • This patent also provides preparation of a retinol emulsion by adding a solution containing retinol to a water-in-oil emulsion.
  • the retinol is added to the emulsion just prior to or at the time of use. It is apparent that the stability of retinol in a composition of this type is insufficient for prolonged storage prior to use.
  • U.S. Patent No. 5,124,313 provides topical compositions having a retinyl ester-polypeptide complex, specifically a retinyl palmitate- polypeptide complex.
  • WO 93/00085 provides stabilization of retinol in cosmetic compositions by addition to the latter a stabilizing complex comprising, in combination, an antioxidant and a chelating agent for chelating metal ions.
  • the stability of the retinol appears enhanced due to considerable amounts of stabilizing antioxidants and chelating agents in the composition.
  • WO 97/02814 provides the preparation of an antibacterial medicament containing a retinoid for rapid bactericidal action, particularly on Gram positive bacteria, which accelerates the repair of small lesions.
  • WO 97/02030 provides cosmetic, antimycotic compositions containing a glycol or glyceryl ester of retinoic acid. These compositions are used to produce visible reduction in wrinkles and visible improvement in tone, firmness and luminosity of skin.
  • the composition can further comprise a cosmetically acceptable carrier.
  • Figure 1 is a plot of the average scores for dryness of lips
  • Figure 2 is a plot of the average scores for dry appearance of lips
  • Figure 3 is a plot of the average scores for clarity of lips
  • Figure 4 is a plot of the average scores for color of lips
  • Figure 5 is a plot of the average scores for line quantity of lips.
  • Figure 6 is a plot of the average scores for line depth of lips.
  • the anatomy and physiology of vagina and the lips of one's mouth differ in many ways from "skin" proper. Because of such differences, the use of a composition having a retinoid, such as retinol, for treating vaginal and lip dryness or treating color deficiency and/or lines of the lip is not an obvious correlation to the treatment of aging pathologies associated with other types of skin.
  • the present invention is the first to demonstrate a clinical benefit when applied topically to a vaginal epithelium and to a semi-mucosal epithelium, which is within and up to the vermilion border of the lips.
  • the present invention is the first to demonstrate that the aesthetic appearance of epithelia is improved by applying a topical composition having both a retinoid, particularly retinol, in an amount effective to improve the aesthetic appearance of the epithelial and a penetration enhancing agent in an amount effective to enhance penetration of the retinoid into the epithelia.
  • a topical composition having both a retinoid, particularly retinol, in an amount effective to improve the aesthetic appearance of the epithelial and a penetration enhancing agent in an amount effective to enhance penetration of the retinoid into the epithelia.
  • the applicants have unexpectedly discovered an effective method for improving human lip color (i.e., increasing redness) and reducing the number and depth of lip lines (i.e., line quantity), as well as re-moisturizing vaginal and lip epithelia in older women.
  • the term "older” refers to post-menopausal women and/or women who suffer from age-related vaginal and lip dryness or cornification.
  • the method of the present invention When used as a vaginal treatment for re-moisturizing vaginal epithelia, the method of the present invention must be applied almost exclusively to older women who are experiencing routine vaginal dryness.
  • the composition is preferably applied daily to inner surfaces of the vagina, before bedtime.
  • epithelial cells may lose responsiveness to circulating retinoids, such as retinol, causing a fundamental change in the structure of the cells, i.e., squamous metaplasia. With a supply of excess retinoid available to the cells, the cells respond and return to their mucosal state.
  • the penetration enhancing agent provides improved delivery of the retinoid to the "active" site located at the epithelial cell.
  • a beneficial re-moisturizing effect is obtained on repeated application of the composition to the vaginal epithelia.
  • the composition is preferably applied to the vaginal epithelia in the form of a cream.
  • a visible improvement in lip condition, moisturization, color, clarity and a measurable reduction in the number and depth of lip lines is observed within a short period of time, which can be as little as two (2) weeks, when applied once or twice a day.
  • the improvement in the color of the lips is manifested by an increase in the redness of the lips, whereas the reduction in the number of lines is directly measured and reduction in the dryness and depth of the lines estimated by direct observation as described below.
  • retinoid includes the following classes of compounds: retinol; esters of retinol with carboxylic acids of 1 to 24 carbon atoms, such as retinyl acetate, retinyl propionate, retinyl butyrate, retinyl octanoate, retinyl laurate, retinyl palmitate, retinyl oleate, retinyl linoleate; esters of retinol with alpha-hydroxy carboxylic acids; ether derivatives of retinol, including alkyl ethers, ethers derived from glycolic acid and glycolate esters and amides, such as retinyl glycolyl ether (retinyl glycolic acid ether); retinaldehyde; retinoic acid; esters of retinoic acid with alcohols of 1 to 24 carbon atoms; isotretinoin as well as synthetic retinoi
  • the retinoid is retinol. More preferably, the retinoid is the trans-isomer of retinol.
  • Retinol may be prepared by well-known methods such as those described in U.S. Patent No. 3,060,229, the content of which is incorporated herein by reference.
  • Retinyl esters which generally are less potent than other retinoids, are less preferred retinoids for the purposes of the present invention. Specifically, retinyl ester-polypeptide complexes, such as those described in U.S. Patent No. 5,124,313, are not contemplated as retinoids within the context of the present invention.
  • the amount of retinoid in the composition of the present invention is preferably in the range from about 0.001 to about 1.5 weight percent (wt%) of the total composition, more preferably from about 0.06 wt% to about 0.3 wt%, and most preferably about 0.1 wt% to about 0.2 wt% of the composition.
  • the amount of retinoid may be adjusted, based upon the potency of the retinoid, without departing from the present invention.
  • the penetration enhancing agent is present in an amount effective to either enhance the penetration of the selected retinoid into the epithelia or increase the rate (i.e., speed) of penetration of the selected retinoid into the epithelia.
  • the penetration enhancing agent does both.
  • the selection of the penetration enhancing agent will depend on formulation factors, such as the chemical properties of the selected retinoid and the vehicle (e.g., solution, emulsion, stick).
  • Non-limiting examples of such penetration enchancing agents include: organic solvents, such as ethanol, glycols (e.g., propylene, butylene, pentylene), pyrrolidones (e.g., 2- pyrrolidone, 1-methyl-2-pyrrolidone, 5-methyl-2-pyrrolidone, 1 ,5-dimethyl-2- pyrrolidone, 1-ethyl-2-pyrrolidone, 2-pyrrolidone carboxylic acid), dimethyl sulfoxide, dimethylacetamide, and dimethylformadide); alkyl sulfoxide; phosphine oxide; sugar esters (e.g., sucrose acetate, sucrose octanoate); anionic surfactants; nonionic surfactants; AzoneTM (e.g., 1-dodecylazaclo- heptan-2-one); N-substituted di-isopropanolamines; fatty acids (e.
  • the composition of the invention can contain a cosmetically acceptable carrier.
  • the carrier can be water, a humectant, a thickener, a gelling agent, an oil, an emulsifier, or mixtures thereof.
  • the resulting composition can be in the form of a cream, dispersion, emulsion, foam, gel, solution, stick suspension, spray, patch, powder or in a towelette.
  • the emulsion can be either an oil-in-water emulsion or a water-in-oil emulsion.
  • the retinoid is formulated into an appropriate vehicle consistent with consumer requirements.
  • the composition can preferably be formulated as a stick or cream for treatment of the lips.
  • the composition would preferably be formulated as a cream.
  • the oil phase of the emulsion preferably has one or more organic compounds, including emollients.
  • the aqueous phase has humectants, such as propylene glycol and glycerin; other water-dispersible or water- soluble components including thickeners such as veegum or hydroxyalkyl cellulose; gelling agents, such as high MW polyacrylic acid, i.e. carbopol 934; and mixtures thereof.
  • the emulsion has one or more emulsifiers capable of emulsifying the various components present in the composition, including the retinoids. Because of the light, heat and air sensitivity of retinoids, retinoids are generally added last in the preformed emulsion so as to minimize exposure to light, heat and oxygen.
  • Non-limiting examples of organic compounds suitable for use in the oil phase include emollients, skin conditioning agents, solvents that are capable of dissolving retinol or retinoids without reducing the stability thereof, and mixtures thereof.
  • the compounds suitable for use in the oil phase include one or more of the following: an alcohol including cetyl alcohol; ester including cetyl recinoleate, sterol esters; carboxylic acid; mineral oil; wax; hydrocarbon; paraffin; isoparaffin; petrolatum; low taste petrolatum for application on lips; hydrogenated polydecene; silicone- containing compound such as dimethyl polysiloxane; and mixtures thereof.
  • the emulsifier can be an emulsifying wax, an emulsifying polyhydric alcohol, a polyether polyol, a polyether, a mono- or di-ester of a polyol, an ethylene glycol mono-stearate, a glycerin mono-stearate, glycerin di- stearate, a silicone-containing emulsifier, a soya sterol, a fatty alcohol such as cetyl alcohol, a fatty acid such as stearic acid, a fatty acid salt, and mixtures thereof.
  • the preferred emulsifiers include soya sterol, cetyl alcohol, stearic acid, emulsifying wax, and mixtures thereof.
  • the emulsifying waxes that are suitable for use in the present invention are well known to persons skilled in the art.
  • the emulsifying wax includes compositions such as those containing about 80 wt% cetearyl alcohol, about 10 wt% polysorbate 60, about 5 wt% stearate, and about 5 wt% steareth-20.
  • the aqueous phase is preferably from about 60 wt% to about 90 wt%
  • the oil phase is preferably from about 5 wt% to about 30 wt% of the emulsion
  • the emulsifier is preferably from about 5% to about 10 wt% of the emulsion.
  • the emulsion according to the present invention has pH preferably in the range from about 6.5 to about 7.5.
  • the composition according to the present invention can be prepared by dissolving a retinoid, such as retinol, in a medium comprising an organic solvent, and optionally water, and adding the resulting homogeneous solution to the emulsion.
  • the composition produced thereby preferably has from about 0.001 wt% to about 1.0 wt% retinol, on an active basis, and about 0.5 wt% to about 1.0 wt% organic solvent. More preferably, the composition has from about 0.06 wt% to about 0.3 wt% retinol.
  • the present invention includes a process for preparing a composition comprising a retinoid, such as retinol, in the form of a cream, dispersion, emulsion, foam, gel, solution, stick or suspension.
  • the process for preparing a composition for re-moisturizing epithelia comprises:
  • preparing a first mixture comprising water, a humectant, a thickener, and a gelling agent; preparing a second mixture comprising an oil and an emulsifier; adding the second mixture and the first mixture together, preferably mixing the second mixture in the first mixture, at a temperature and period of time sufficient to produce a stable emulsion; cooling the stable emulsion; and adding a retinoid to the stable emulsion to produce the composition.
  • the present invention may include a secondary component.
  • the secondary component is preferably selected from one or more of the following thirteen groups.
  • Rexinoids include compounds, such as all-trans retinoic acid, 9-cis retinoic acid, phytanic acid and others, that bind to RXR receptors.
  • An estrogen synthetase (aromatase) stimulating compound is an estrogen synthetase (aromatase) stimulating compound:
  • Examples of such a compound include caffeine and/or derivatives thereof, and any mixture thereof.
  • Caffeine is the more preferred of such compounds.
  • Examples of such a compound include linolenic acid, linoleic acid, finasteride, and mixtures thereof.
  • An exfoliation promoting compound Suitable examples include alpha hydroxy acids; beta hydroxy acids; oxa acids as disclosed in U.S. Patent No. 5,847,003 (the disclosure of which is incorporated herein by reference); oxa diacids as disclosed in U.S. Patent No.
  • the preferred exfoliation promoting compounds are lactic acid, glycolic acid, 3,6,9-trioxaundecanedioic acid, and any mixture thereof.
  • the composition comprises about 1 wt% to 20 wt%, preferably about 1 wt% to about 15 wt%, more preferably about 4 wt% to about 10 wt% acid, and most preferably about 4 wt%, of the exfoliation promoting compound.
  • An ultraviolet (UV) light protecting/sunscreen agent examples include organic and inorganic sunscreens, such as titanium dioxide, zinc oxide, methyl benzylidene camphor and/or its derivatives, octocrylene, anthranilates, benzophenones, butylmethoxydibenzoylmethane
  • a preferred UV absorber includes a hydroxybenzophenone derivative, a benzotriazole derivative, a dibenzoyl methane derivative, an oxanilide derivative, a hydroxy cinnamate derivative, and mixtures thereof.
  • Co-formulation with an ultraviolet light protecting/sunscreen agent is particularly desirable when the present invention is used for treating lip epithelia, particularly for users who engage in activities, particularly outdoor activities, which expose the user's lip epithelia to UV radiation.
  • Non-limiting examples of such activities include indoor tanning, sunbathing, and skiing.
  • the sunscreen comprises from about 2 wt% to about 20 wt%, more preferably about 2 wt% to about 15 wt%, of the total weight of the composition.
  • Barrier function enhancing agents examples include ceramides; essential fatty acids and their esters, especially glycerides, ⁇ -hydroxy fatty acids and their esters, ⁇ -hydroxy fatty acids and their esters; phospholipids; cholesterol and its esters, such as cholesteryl hemisuccinate, cholesteryl phosphate; and cholestanol and its derivatives.
  • the barrier function enhancing agent can be added to a topical composition either as singular molecular entities or as a complex mixture of lipids derived from either synthetic, animal or plant sources.
  • Collagen enhancing agents These agents prevent epithelia "sagging" by promoting a net increase in collagen, either by reducing collagen breakdown or by promoting collagen formation.
  • examples of such agents include Clara extract (Sophora augustifolia), ascorbyl-phoshoryl- cholesterol, ascorbic acid, ascorbic acid derivatives, and mixtures thereof.
  • Elastase inhibitors examples include fatty acids, such as oleic acid, perinaric acid, and Honeysuckle extract (Lonicera caprifolium). These inhibitors act to prevent sagging of the epithelia.
  • Skin lightening agents examples include kojic acid, hydroquinone, licorice derivatives, ascorbic acid/ascorbic acid derivatives (e.g. magnesium ascorbyl phosphate), arbutin, bearberry (Arctostaphylos uva ursi), Glycyrrhiza glabra and its derivatives, Chlorella vulgaris extract, and mixtures thereof.
  • Antioxidants examples include compounds having phenolic hydroxy functions, such as ascorbic acid, ascorbic acid derivatives; gallic acid derivatives (e.g. propyl gallate); ferulic acid derivatives (e.g. ethyl ferulate, sodium ferulate); nitrones; N-tertbutyl-nitrone; I-(4-pyridyl-1-oxide)- N-tertbutyl-nitrone; curcumin, tetrahydrocurcumin; 6-hydroxy- 2,5,7,tetramethylchroman-2-carboxylic acid; uric acid; reductic acid; tannic acid; rosmarinic acid; tocopherol and its derivatives; catechins; and mixtures thereof.
  • phenolic hydroxy functions such as ascorbic acid, ascorbic acid derivatives; gallic acid derivatives (e.g. propyl gallate); ferulic acid derivatives (e.g. ethyl ferulate, sodium ferulate); nitro
  • antioxidants are those that have one or more thiol functions (-SH), in either reduced or non-reduced form, such as glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds.
  • the antioxidant may be inorganic, such as sulfites, bisulfites, metabisulfite, or other inorganic salts and acids containing sulfur.
  • the antioxidant is selected from the group consisting of: a phenolic antioxidant such as butylated hydroxytoluene; butylated hydroxyanisole; an alkyl paraben such as methyl, ethyl or propyl paraben; and any mixtures thereof.
  • Skin warming agents examples include vanillyl butylamid, capsaicin, and mixtures thereof.
  • Skin cooling compounds examples include menthol, menthyl glycerol, asymmetrical carbonates, thiocarbonates and urethanes, N- substituted carboxamides, ureas or phosphine oxides, menthyl lactate, menthone glycerine acetal, and any mixtures thereof.
  • Anti-pruretic/Anti-itch compounds Non-limiting examples of such compounds include capsaicin, nonivamde, and corticosteroids. Co- formulation with an anti-pruretic/anti-itch compound may be desirable when the present invention is applied to itchy vaginal epithelia. A non-limiting example of when such co-formulation may be desirable includes when the user has a concurrent condition commonly referred to as a yeast (Candida albicans) infection.
  • compositions of the present invention may include at least two secondary components, with each secondary component being selected from a different group.
  • compositions of the present invention can include other cosmetic and pharmaceutical actives and excipients.
  • suitable cosmetic and pharmaceutical agents include, but are not limited to, one or more of erythromycins, tetracyclines, salicylic acids, antifungals, vitamins, anti-inflammatory agents, antimicrobials, analgesics, nitric oxide synthase inhibitors, self-tanning agents, surfactants, moisturizers, stabilizers, preservatives, antiseptics, chelating agents, thickeners, emulsifiers, lubricants, humectants, chelating agents, skin penetration enhancers, skin cooling agents, emollients, fragrances, colorants, flavoring agents, pigments, and mixtures thereof.
  • additives include: vitamins, such as tocopherol and ascorbic acid; vitamin derivatives such as ascorbyl monopalmitate; thickeners such as hydroxyalkyl cellulose; gelling agents; structuring agents such as bentonite, smectite, magnesium aluminum silicate and lithium magnesium silicate; metal chelating agents such as EDTA; pigments such as zinc oxide and titanium dioxide; colorants; emollients; and humectants.
  • compositions of the present invention may be non-pigmented or pigmented.
  • Lip compositions such as lipsticks, often have pigments incorporated therein.
  • An example of a pigment is iron oxides.
  • the composition when the composition is pigmented, it is preferred that the composition includes an ascorbyl-phosphoryl-cholesterol (APC) compound.
  • APC ascorbyl-phosphoryl-cholesterol
  • suitable APC compounds are disclosed in WO 97/42960, which is commonly assigned and is incorporated herein by reference.
  • an APC compound in pigmented compositions of the present invention is particularly desirable when the pigment is an iron oxide.
  • An example of such a pigmented composition may have from about 0.2 wt% to about 20 wt% of iron oxides in addition to the APC compound.
  • One preferred example of such a topical composition has from about 5 wt% to about 7 wt% of iron oxides and about 1 wt% of the APC compound in a suitable vehicle.
  • the iron oxides are selected from the group consisting of iron oxide red 2259-preserved, iron oxides (yellow), iron oxides (black), and mixtures thereof. Additional advantages of including an APC compound are set forth in PCT WO 00/06091 , which is commonly assigned and is incorporated herein by reference.
  • compositions of the present invention can be applied to epithelia for a period of time to improve the aesthetic appearance of the epithelia.
  • the improvement in aesthetics can include at least one of the following: a. reducing intrinsic aging; b. reducing photoaging; c. decreasing epithelial fragility; d. preventing and reversing loss of collagen; e. preventing epithelial atrophy; f. promoting/accelerating cell turnover; g.
  • Efficacy of retinol-containing creams in reducing visible signs of aging lips was demonstrated as follows. Two lip creams, Lip Cream A containing 0.15% active retinol and Lip Cream B containing 0.30% active retinol were prepared as shown below in TABLE 1.
  • the subjects were randomly divided into two groups and each group was asked to use one Lip Cream once a day, at night, shortly before bedtime, after cleansing their face prior to using the Lip Cream. They were asked to apply a small amount of product onto a finger and spread the product on both the upper and lower lip, avoiding the outer edges of the lips, with the lips closed, to avoid getting the product into the mouth.
  • the use of usual lip products such as lipstick and/or lip balm was permitted except on examination days.
  • Lip Cream A and Lip Cream B were then dispensed and use instructions administered. Briefly, subjects were instructed to apply the test product to their lips once a day, before bedtime.
  • retinol revealed a 68% improvement in lip color and 28% reduction in the number of vertical lip lines and 30% reduction in the depth of vertical lip lines within 8 weeks of treatment.
  • Cream B was not large, the magnitude of improvements in dryness, dry appearance, color, clarity and lines of the lips obtained from Lip Cream A containing 0.3% retinol was greater for all measured parameters. In addition, both Lip Cream A and Lip Cream B were clinically well tolerated.
  • FIGS 1 through 6 chart the average scores for each parameter. These graphs demonstrate that, for all parameters, the most dramatic improvement was observed between 2 and 4 weeks of Lip Cream use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une méthode de traitement efficace pour améliorer l'aspect de l'épithélium, tel que l'épithélium des lèvres et du vagin. La méthode de l'invention consiste à appliquer localement une quantité efficace d'une composition contenant un rétinoïde, de préférence dans un véhicule acceptable au plan cosmétique, sur l'épithélium du vagin ou des lèvres. L'invention concerne également des compositions pour la mise en oeuvre de la méthode.
EP00928558A 1999-04-29 2000-04-28 Methode pour ameliorer l'aspect esthetique de l'epithelium Ceased EP1173148A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30157099A 1999-04-29 1999-04-29
US301570 1999-04-29
PCT/US2000/011529 WO2000066077A1 (fr) 1999-04-29 2000-04-28 Methode pour ameliorer l'aspect esthetique de l'epithelium

Publications (2)

Publication Number Publication Date
EP1173148A1 true EP1173148A1 (fr) 2002-01-23
EP1173148A4 EP1173148A4 (fr) 2002-07-24

Family

ID=23163959

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00928558A Ceased EP1173148A4 (fr) 1999-04-29 2000-04-28 Methode pour ameliorer l'aspect esthetique de l'epithelium

Country Status (4)

Country Link
EP (1) EP1173148A4 (fr)
AU (1) AU4677600A (fr)
CA (1) CA2370633A1 (fr)
WO (1) WO2000066077A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103528D0 (sv) * 2001-10-21 2001-10-21 Jan Faergeman Topiska kompositioner med förstärkt effekt
DE10224456A1 (de) * 2002-06-03 2004-01-22 Beiersdorf Ag Verwendung von Jelängerjelieber-Blütenextrakt zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe und Behandlung von entzündlic hen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter Haut
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0609963A1 (fr) * 1988-11-29 1994-08-10 Janssen Pharmaceutica N.V. Utilisation des dérivés du benzimidazole et du benzotriazole dans le traitement des troubles épithéliaux
US5616572A (en) * 1991-11-25 1997-04-01 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536740A (en) * 1995-06-01 1996-07-16 Elizabeth Arden Company, Division Of Conopco, Inc. Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0609963A1 (fr) * 1988-11-29 1994-08-10 Janssen Pharmaceutica N.V. Utilisation des dérivés du benzimidazole et du benzotriazole dans le traitement des troubles épithéliaux
US5616572A (en) * 1991-11-25 1997-04-01 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0066077A1 *

Also Published As

Publication number Publication date
WO2000066077A1 (fr) 2000-11-09
CA2370633A1 (fr) 2000-11-09
AU4677600A (en) 2000-11-17
EP1173148A4 (fr) 2002-07-24

Similar Documents

Publication Publication Date Title
US20050281766A1 (en) Method of improving the aesthetic appearance of epithelia
CA2264877C (fr) Traitement labial contenant un derive de cellules de levure vivantes
US10016356B2 (en) Sebum secretion inhibitory agent
CA3055669A1 (fr) Methodes de traitement de la peau
KR20080070621A (ko) 신규 피부 관리 조성물
KR101917774B1 (ko) 블랙커민씨드 추출물을 유효성분으로 포함하는 화장품 보존용 조성물
US20080057138A1 (en) Restorative skin cream
JP2005518399A (ja) 皮膚の審美的外観を改善するための方法
WO2018075810A1 (fr) Compositions dermatologiques pour fournir des nutriments à la peau et procédés associés
EP1192939A2 (fr) Méthodes pour réduire l'inflammation et l'érythème
WO2017100873A1 (fr) Composition cosmétique et son utilisation
JP2008100963A (ja) 化粧料
BR112013024572B1 (pt) Processo cosmético e uso cosmético de pelo menos um composto de fórmula (I)
US9572767B2 (en) Luminate hand cream
KR100371028B1 (ko) 피부안전성이 우수하면서 여드름 예방 및 치료에 효과가있는 단삼추출물 및 폴리에톡실화 레틴아미드 함유 화장료조성물
JP2016216435A (ja) 評価方法
CN116583264A (zh) 包含蔗糖酯和溶剂的化妆品组合物
EP1173148A1 (fr) Methode pour ameliorer l'aspect esthetique de l'epithelium
JP5746807B2 (ja) 皮膚用化粧品の組成物
CN116546966A (zh) 制造包含蔗糖酯和溶剂的化妆品组合物的方法
JP7305161B2 (ja) 皮膚化粧料
WO2020201377A1 (fr) Crème pour le traitement de la peau lésée par le soleil
JP2004051610A (ja) 美白化粧料
JP2004269433A (ja) 化粧料組成物
JP2020015699A (ja) 皮膚化粧料

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020610

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 7/42 A, 7A 61K 7/025 B, 7A 01N 25/34 B, 7A 01N 31/04 B, 7A 61K 7/48 B, 7A 61K 31/07 B

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090928